Literature DB >> 12930548

The International Sepsis Forum's frontiers in sepsis: High cardiac output should be maintained in severe sepsis.

Jean-Louis Vincent1.   

Abstract

Entities:  

Mesh:

Year:  2003        PMID: 12930548      PMCID: PMC270704          DOI: 10.1186/cc2349

Source DB:  PubMed          Journal:  Crit Care        ISSN: 1364-8535            Impact factor:   9.097


× No keyword cloud information.

Introduction

Sepsis is associated with systemic, mediator-induced alterations in oxygen utilization, including increased oxygen demand, altered oxygen extraction, and decreased myocardial contractility (Fig. 1). Hence, despite a normal or high cardiac output, severe sepsis and septic shock are characterized by an inadequate organ oxygenation, leading ultimately to multiple organ failure and death. Almost 20 years ago, Abraham and colleagues [1] noted that survivors from septic shock had significantly higher cardiac indexes prior to the shock episode than did nonsurvivors, leading to the suggestion that pushing patients to reach high and even 'supranormal' levels of cardiac output could be beneficial. This early hypothesis has fueled an ongoing debate regarding the potential benefit or harm of this strategy in the patient with septic shock.
Figure 1

Influence of sepsis mediators on the relationship between oxygen uptake and delivery.

The 'supranormal' studies

Several groups have indicated increased survival in various groups of patients treated with a strategy to increase cardiac output or oxygen delivery (DO2) to so-called 'supranormal' values (cardiac index ≥ 4.5 l/min per m2, DO2 < 600 ml/min per m2 and oxygen consumption [VO2] >170 ml/min per m2) [2-9]. However, two notable studies conducted in mixed groups of critically ill patients by Hayes and coworkers [10] and Gattinoni and coworkers [11] showed that supranormal DO2 values do not result in improved outcomes. A possible explanation for those findings is that, unlike many of the other studies in this field, the heterogeneity of the critically ill patients included in the studies influenced the results. Thus, although some individuals might well have benefited from the trial strategy, these positive results may have been negated by harmful effects in other patients who perhaps had already been adequately resuscitated and therefore received excessive doses of vasopressor agents or fluids. There is little doubt that, in certain patients, achieving and maintaining high levels of cardiac output is associated with improved outcomes; the difficulty lies in identifying those patients.

Should we maintain adequate cardiac output in all patients with septic shock?

The available studies suggest that rather than protocolize all patients to increased cardiac output and DO2, this strategy should be tailored to the individual patient. Hayes and coworkers [6] suggested that survivors from septic shock are characterized by an ability to increase DO2 and VO2, whereas nonsurvivors do not have sufficient physiologic reserve to do this, and in such patients excessive doses of vasopressors or fluids worsen an already bad situation. Rather than making attempts to target cardiac output and DO2 randomly in all patients, our approach should rather be to try to restore hemodynamic stability, which will necessitate different approaches in different patients. Indeed, no one would dispute the need for clinical interventions to enhance DO2 and support the circulation where tissue perfusion is clearly inadequate. The problem lies in identifying those patients in whom tissue hypoxia is less overt, who may in fact have 'normal' hemodynamic parameters, and augmenting DO2 in such patients may necessitate reaching 'supranormal' values. So, how can we determine which patients require what therapy? Perhaps the mixed venous oxygen saturation (SvO2) is the most important parameter to follow. SvO2 provides an indication of the degree of oxygen extracted by the organs before the blood returns to the right heart and hence gives a measure of the balance between DO2 and VO2, thus providing an indication of the ability of the cardiac output to meet the individual's oxygenation needs. Admittedly, SvO2 is a global parameter and gives no specific regional information, but neither does cardiac output; in fact, it may be interesting to combine SvO2 and cardiac output (Fig. 2). Indeed, this is one of the problems with the less invasive methods of measuring cardiac output; we are all agreed that 'less invasive' is the way to go, but how does one interpret cardiac output values without knowledge of the SvO2? Some may say that SvO2 monitoring is useless in sepsis or septic shock because, in sepsis, SvO2 may be normal or high despite regional tissue hypoxia, because of altered tissue oxygen extraction. However, clinical evidence shows that SvO2 does fluctuate in patients with sepsis or septic shock [12], and there are two major arguments in support of the value of SvO2 monitoring in sepsis. First, Ronco and coworkers [13] noted that patients who are about to die may still have high oxygen extraction capabilities. Hence, in septic shock, a high or normal SvO2 does not necessarily mean that oxygen extraction cannot increase further. Second, Rivers and coworkers [14] showed, in a patient population treated in an emergency department, that the initial central venous oxygen saturation (measured as a substitute for SvO2) was only 48.6 ± 11.2%. Hence, it is only after initial resuscitation that central venous oxygen saturation (or SvO2) may reach normal (or supranormal) values. Conversely, it may decrease again if there is hypovolemia or myocardial depression.
Figure 2

Interpretation of cardiac output according to mixed venous oxygen saturation (SvO2) values. VO2, oxygen consumption.

Importantly, it is not necessary to calculate DO2. Moreover, the relationship between VO2 and DO2 is subject to mathematical coupling of data. In complex cases, the relation between cardiac index and oxygen extraction ratio may be helpful, especially in anemia [15,16]. Finally, blood lactate levels may help to identify the patient who requires a higher cardiac output because survivors from septic shock have significantly lower initial blood lactate levels and their blood lactate levels are raised for shorter periods of time [17]. Another important feature may be the timing of optimization. In the early studies conducted by Shoemaker and coworkers [2] that showed improved outcome in surgical patients, optimization was commenced before the surgical procedure. Rivers and coworkers [14] recently showed the beneficial effects of early goal-directed therapy, within 6 hours of diagnosis of septic shock, over standard therapy. The methods for increasing cardiac output or DO2 (e.g. fluids, inotropes, and blood transfusions) may also impact on results.

Conclusion

More important than achieving supranormal DO2 and, hence, oxygen consumption in those patients who may benefit from this strategy is achieving optimal hemodynamic status in all patients (Fig. 3). If augmentation of DO2 is associated with a reduction in serum lactate levels and improved target organ perfusion, then these interventions may be continued. Each patient must be assessed according to their clinical (urine output, skin perfusion, mental status), hemodynamic (arterial pressure, cardiac output), and oxygenation (SvO2, blood lactate) parameters. Practising good medicine is never simple, and applying protocols to reach supranormal DO2 in all patients is naïve. The challenge is to identify which approach is needed in which patient so that all patients receive optimal care.
Figure 3

Schematic showing the combination of variables involved in the assessment of the patient with septic shock.

Competing interests

None declared.

Abbreviations

DO2 = oxygen delivery; SvO2 = mixed venous oxygen saturation; VO2 = oxygen consumption.
  17 in total

1.  Oxygen transport patterns in patients with sepsis syndrome or septic shock: influence of treatment and relationship to outcome.

Authors:  M A Hayes; A C Timmins; E H Yau; M Palazzo; D Watson; C J Hinds
Journal:  Crit Care Med       Date:  1997-06       Impact factor: 7.598

2.  A trial of goal-oriented hemodynamic therapy in critically ill patients. SvO2 Collaborative Group.

Authors:  L Gattinoni; L Brazzi; P Pelosi; R Latini; G Tognoni; A Pesenti; R Fumagalli
Journal:  N Engl J Med       Date:  1995-10-19       Impact factor: 91.245

3.  Endpoints of resuscitation of critically injured patients: normal or supranormal? A prospective randomized trial.

Authors:  G C Velmahos; D Demetriades; W C Shoemaker; L S Chan; R Tatevossian; C C Wo; P Vassiliu; E E Cornwell; J A Murray; B Roth; H Belzberg; J A Asensio; T V Berne
Journal:  Ann Surg       Date:  2000-09       Impact factor: 12.969

4.  The relation between cardiac index and oxygen extraction in acutely ill patients.

Authors:  P G Silance; C Simon; J L Vincent
Journal:  Chest       Date:  1994-04       Impact factor: 9.410

5.  Mixed venous oxygen saturation in critically ill septic shock patients. The role of defined events.

Authors:  P Krafft; H Steltzer; M Hiesmayr; W Klimscha; A F Hammerle
Journal:  Chest       Date:  1993-03       Impact factor: 9.410

6.  Elevation of systemic oxygen delivery in the treatment of critically ill patients.

Authors:  M A Hayes; A C Timmins; E H Yau; M Palazzo; C J Hinds; D Watson
Journal:  N Engl J Med       Date:  1994-06-16       Impact factor: 91.245

7.  Prospective, randomized trial of survivor values of cardiac index, oxygen delivery, and oxygen consumption as resuscitation endpoints in severe trauma.

Authors:  M H Bishop; W C Shoemaker; P L Appel; P Meade; G J Ordog; J Wasserberger; C J Wo; D A Rimle; H B Kram; R Umali
Journal:  J Trauma       Date:  1995-05

8.  Identification of the critical oxygen delivery for anaerobic metabolism in critically ill septic and nonseptic humans.

Authors:  J J Ronco; J C Fenwick; M G Tweeddale; B R Wiggs; P T Phang; D J Cooper; K F Cunningham; J A Russell; K R Walley
Journal:  JAMA       Date:  1993-10-13       Impact factor: 56.272

9.  Response of critically ill patients to treatment aimed at achieving supranormal oxygen delivery and consumption. Relationship to outcome.

Authors:  M A Hayes; E H Yau; A C Timmins; C J Hinds; D Watson
Journal:  Chest       Date:  1993-03       Impact factor: 9.410

10.  Serial blood lactate levels can predict the development of multiple organ failure following septic shock.

Authors:  J Bakker; P Gris; M Coffernils; R J Kahn; J L Vincent
Journal:  Am J Surg       Date:  1996-02       Impact factor: 2.565

View more
  5 in total

1.  Terlipressin in patients with septic shock: friend or foe?

Authors:  M Westphal; C Ertmer; H Van Aken; H-G Bone
Journal:  Intensive Care Med       Date:  2004-03-27       Impact factor: 17.440

2.  A cardiovascular drug rescues mice from lethal sepsis by selectively attenuating a late-acting proinflammatory mediator, high mobility group box 1.

Authors:  Wei Li; Jianhua Li; Mala Ashok; Rongqian Wu; Dazhi Chen; Lihong Yang; Huan Yang; Kevin J Tracey; Ping Wang; Andrew E Sama; Haichao Wang
Journal:  J Immunol       Date:  2007-03-15       Impact factor: 5.422

Review 3.  [Vasopressin and terlipressin in sepsis and systemic inflammatory response syndrome. Effects on microcirculation, oxygen transport, metabolism and organ function].

Authors:  C Ertmer; A W Sielenkämper; H van Aken; H-G Bone; M Westphal
Journal:  Anaesthesist       Date:  2005-04       Impact factor: 1.041

4.  Dobutamine reverses the vasopressin-associated impairment in cardiac index and systemic oxygen supply in ovine endotoxemia.

Authors:  Christian Ertmer; Andrea Morelli; Hans-Georg Bone; Henning Dirk Stubbe; Ralf Schepers; Hugo Van Aken; Matthias Lange; Katrin Bröking; Martin Lücke; Daniel L Traber; Martin Westphal
Journal:  Crit Care       Date:  2006       Impact factor: 9.097

5.  Gastric tonometry versus cardiac index as resuscitation goals in septic shock: a multicenter, randomized, controlled trial.

Authors:  Fernando Palizas; Arnaldo Dubin; Tomas Regueira; Alejandro Bruhn; Elias Knobel; Silvio Lazzeri; Natalio Baredes; Glenn Hernández
Journal:  Crit Care       Date:  2009-03-31       Impact factor: 9.097

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.